Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.

Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.

PMID:
29607465
3.

Combined chemoembolization and thermal ablation for the treatment of metastases to the liver.

Alexander ES, Mick R, Nadolski GJ, Mondschein JI, Stavropoulos SW, Soulen MC.

Abdom Radiol (NY). 2018 Oct;43(10):2859-2867. doi: 10.1007/s00261-018-1536-x.

PMID:
29500644
4.

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.

Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614. doi: 10.1007/s00280-018-3519-6. Epub 2018 Jan 23.

PMID:
29362902
5.

The notch pathway is activated in neoplastic progression in esophageal squamous cell carcinoma.

Lubin DJ, Mick R, Shroff SG, Stashek K, Furth EE.

Hum Pathol. 2018 Feb;72:66-70. doi: 10.1016/j.humpath.2017.11.004. Epub 2017 Nov 12.

PMID:
29137934
6.

Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy.

Ahn PH, Finlay JC, Gallagher-Colombo SM, Quon H, O'Malley BW Jr, Weinstein GS, Chalian A, Malloy K, Sollecito T, Greenberg M, Simone CB 2nd, McNulty S, Lin A, Zhu TC, Livolsi V, Feldman M, Mick R, Cengel KA, Busch TM.

Photodiagnosis Photodyn Ther. 2018 Mar;21:28-35. doi: 10.1016/j.pdpdt.2017.10.015. Epub 2017 Nov 4.

PMID:
29113960
7.

Aggregation behavior and reproductive compatibility in the family Cimicidae.

DeVries Z, Mick R, BalvĂ­n O, Schal C.

Sci Rep. 2017 Oct 13;7(1):13163. doi: 10.1038/s41598-017-12735-3.

8.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

9.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R.

Blood. 2017 Feb 16;129(7):906-916. doi: 10.1182/blood-2016-08-735076. Epub 2017 Jan 5.

10.

Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.

Narayan V, Vapiwala N, Mick R, Subramanian P, Christodouleas JP, Bekelman JE, Deville C, Rajendran R, Haas NB.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):355-361. doi: 10.1016/j.ijrobp.2016.10.013. Epub 2016 Oct 20.

PMID:
27986349
11.

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ.

Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.

12.

Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.

De La Cruz LM, McDonald ES, Mick R, Datta J, Nocera NF, Xu S, Fisher CS, Czerniecki BJ.

Ann Surg Oncol. 2017 Apr;24(4):1057-1063. doi: 10.1245/s10434-016-5651-z. Epub 2016 Nov 8.

PMID:
27826664
13.

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.

Chao HH, Berman AT, Simone CB 2nd, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP.

J Thorac Oncol. 2017 Feb;12(2):281-292. doi: 10.1016/j.jtho.2016.10.018. Epub 2016 Nov 5.

14.

Feel the heat: activation, orientation and feeding responses of bed bugs to targets at different temperatures.

DeVries ZC, Mick R, Schal C.

J Exp Biol. 2016 Dec 1;219(Pt 23):3773-3780. Epub 2016 Sep 29.

15.

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ.

Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017.

16.

Percutaneous biliary drainage effectively lowers serum bilirubin to permit chemotherapy treatment.

Levy JL, Sudheendra D, Dagli M, Mondschein JI, Stavropoulos SW, Shlansky-Goldberg RD, Trerotola SO, Teitelbaum U, Mick R, Soulen MC.

Abdom Radiol (NY). 2016 Feb;41(2):317-23. doi: 10.1007/s00261-015-0580-z.

PMID:
26867914
17.

Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Ahn PH, Quon H, O'Malley BW, Weinstein G, Chalian A, Malloy K, Atkins JH, Sollecito T, Greenberg M, McNulty S, Lin A, Zhu TC, Finlay JC, Cengel K, Livolsi V, Feldman M, Mick R, Busch TM.

Oral Oncol. 2016 Apr;55:37-42. doi: 10.1016/j.oraloncology.2016.01.013. Epub 2016 Feb 8.

18.

A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer.

Fernandes A, Berman AT, Mick R, Both S, Lelionis K, Lukens JN, Ben-Josef E, Metz JM, Plastaras JP.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):483-7. doi: 10.1016/j.ijrobp.2015.12.005. Epub 2015 Dec 14.

PMID:
26847847
19.

Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.

Mick R, Chen TT.

Cancer Immunol Res. 2015 Dec;3(12):1292-8. doi: 10.1158/2326-6066.CIR-15-0260. Review.

20.

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.

21.

Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ.

Oncoimmunology. 2015 Apr 1;4(10):e1022301. eCollection 2015 Oct.

22.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.

J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8.

23.

Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.

Ford PA, Grant SJ, Mick R, Keck G.

J Clin Oncol. 2015 May 20;33(15):1674-9. doi: 10.1200/JCO.2014.57.9912. Epub 2015 Apr 13.

24.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

25.

Suspension of accrual in phase II cancer clinical trials.

Li Y, Mick R, Heitjan DF.

Clin Trials. 2015 Apr;12(2):128-38. doi: 10.1177/1740774514562029. Epub 2015 Jan 7.

26.

A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.

Fang P, Mick R, Deville C, Both S, Bekelman JE, Christodouleas JP, Guzzo TJ, Tochner Z, Hahn SM, Vapiwala N.

Cancer. 2015 Apr 1;121(7):1118-27. doi: 10.1002/cncr.29148. Epub 2014 Nov 25.

27.

Classifying ultra-high risk smoldering myeloma.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM.

Leukemia. 2015 Mar;29(3):751-3. doi: 10.1038/leu.2014.313. Epub 2014 Nov 5. No abstract available.

PMID:
25371175
28.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.

Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

29.

Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.

Garfall AL, Dougherty AL, Vogl DT, Weiss BM, Cohen AD, Mick R, O'Doherty U, Stadtmauer EA.

Bone Marrow Transplant. 2014 Nov;49(11):1439-41. doi: 10.1038/bmt.2014.153. Epub 2014 Jul 21. No abstract available.

30.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10.

31.

Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.

Lin LL, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR.

Oncol Lett. 2014 Apr;7(4):1151-1158. Epub 2014 Feb 5.

32.

Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation.

Berman AT, Turowski J, Mick R, Cengel K, Farnese N, Basel-Brown L, Mesaros C, Blair I, Lawson J, Christofidou-Solomidou M, Lee J, Rengan R.

J Pulm Respir Med. 2013 Aug 30;3(4):154.

33.

Effects of solar particle event proton radiation on parameters related to ferret emesis.

Sanzari JK, Wan XS, Krigsfeld GS, King GL, Miller A, Mick R, Gridley DS, Wroe AJ, Rightnar S, Dolney D, Kennedy AR.

Radiat Res. 2013 Aug;180(2):166-76. doi: 10.1667/RR3173.1. Epub 2013 Jul 24.

34.

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.

Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P, Czerniecki BJ.

Ann Surg Oncol. 2013 Oct;20(10):3233-9. doi: 10.1245/s10434-013-3119-y. Epub 2013 Jul 13.

PMID:
23851609
35.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

36.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C.

Clin Lung Cancer. 2013 Sep;14(5):581-91. doi: 10.1016/j.cllc.2013.05.002. Epub 2013 Jul 1.

37.

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J.

Am J Hematol. 2013 Oct;88(10):890-4. doi: 10.1002/ajh.23524. Epub 2013 Aug 1.

38.

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C.

Lung Cancer. 2013 Sep;81(3):347-53. doi: 10.1016/j.lungcan.2013.05.011. Epub 2013 Jun 24.

39.

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G.

J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.

40.

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O.

Oncoimmunology. 2013 Jan 1;2(1):e23033.

41.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.

42.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.

N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.

43.

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH.

Sci Transl Med. 2012 May 16;4(134):134ra62. doi: 10.1126/scitranslmed.3003330.

44.

Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D, Punekar S, Glatstein E, Cengel K.

Ann Thorac Surg. 2012 May;93(5):1658-65; discussion 1665-7. doi: 10.1016/j.athoracsur.2012.02.009.

45.

A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Li Y, Mick R, Heitjan DF.

Clin Trials. 2012 Jun;9(3):293-302. doi: 10.1177/1740774512443429. Epub 2012 Apr 20.

46.

A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.

Rengan R, Mick R, Pryma D, Rosen MA, Lin LL, Maity AM, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Prendergast S, Sharkoski T, Hahn SM.

J Thorac Oncol. 2012 Apr;7(4):709-15. doi: 10.1097/JTO.0b013e3182435aa6.

47.

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ.

Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17.

48.

Comparison of hindlimb unloading and partial weight suspension models for spaceflight-type condition induced effects on white blood cells.

Wilson JM, Krigsfeld GS, Sanzari JK, Wagner EB, Mick R, Kennedy AR.

Adv Space Res. 2012 Jan 1;49(2):237-248.

49.

Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ Jr, Coukos G.

PLoS One. 2011;6(12):e28732. doi: 10.1371/journal.pone.0028732. Epub 2011 Dec 14.

50.

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ.

J Immunother. 2012 Jan;35(1):54-65. doi: 10.1097/CJI.0b013e318235f512.

Supplemental Content

Support Center